6831-82-9

Usage

Uses

Used in Organic Synthesis:
Potassium isopropoxide is used as a reagent in organic synthesis for various applications, such as the formation of ethers, deprotonation, and base-catalyzed reactions. Its strong basic nature allows it to deprotonate weak acids, making it a versatile compound in the synthesis of various organic molecules.
Used in Pharmaceuticals:
In the pharmaceutical industry, potassium isopropoxide is used as an intermediate in the synthesis of various drugs. Its ability to act as a nucleophile and a base makes it a valuable component in the production of pharmaceutical compounds.
Used in Agrochemicals:
Potassium isopropoxide is also utilized in the agrochemical industry as a raw material and intermediate for the synthesis of various agrochemical products, such as pesticides and fertilizers.
Used in Colorants and Aroma Chemicals:
Potassium isopropoxide is used as a reagent in the production of colorants and aroma chemicals, where its strong basic nature aids in the synthesis of these compounds.
Used in Detergents and Biodiesel:
In the manufacturing of detergents and biodiesel, potassium isopropoxide is used as a catalyst to facilitate the reactions required for the production of these products.
Used in Polymerization and Isomerizations:
Potassium isopropoxide acts as a catalyst in polymerization and isomerization reactions, where it helps to initiate and control the formation of polymers and the rearrangement of molecular structures.

InChI:InChI=1/C3H7O.K/c1-3(2)4;/h3H,1-2H3;/q-1;+1

Upstream product

• 67-63-0 isopropyl alcohol 

Downstream Products

• 139-24-2 3,3'-dichloroazoxybenzene 
• 23377-24-4 bis-(3-bromo-phenyl)-diazene-N-oxide 
• 100-02-7 4-nitro-phenol 
• 26455-31-2 1-isopropoxy-4-nitrobenzene 
• 106-47-8 4-chloro-aniline 
• 614-26-6 4,4'-bis(chloro)azoxybenzene 
• 1602-00-2 bis-(4-chloro-phenyl)-diazene 
• 38753-50-3 1-isopropoxy-2-nitrobenzene 
• 98-95-3 nitrobenzene 
• 13556-84-8 2,2'-azoxychlorobenzene 
• 140-92-1 potassium isopropylxanthate 
• 618-23-5 1-isopropoxy-4-(trifluoromethyl)benzene 
• 1187772-01-5 [Pb(isopropoxide)(CH(C(Me)N(2,6-iPr₂C₆H₃))2)] 
• 1206805-07-3 (7Z)-7-benzylidene-5-isopropoxy-2-methylthio-4-pyrrolidin-1-yl-5,7-dihydrofuro[3,4-d]pyrimidine 

Relevant academic research and scientific papers

Manganese-Mediated C-C Bond Formation: Alkoxycarbonylation of Organoboranes

Alkoxycarbonylations are important and versatile reactions that result in the formation of a new C-C bond. Herein, we report on a new and halide-free alkoxycarbonylation reaction that does not require the application of an external carbon monoxide atmosphere. Instead, manganese carbonyl complexes and organo(alkoxy)borate salts react to form an ester product containing the target C-C bond. The required organo(alkoxy)borate salts are conveniently generated from the stoichiometric reaction of an organoborane and an alkoxide salt and can be telescoped without purification. The protocol leads to the formation of both aromatic and aliphatic esters and gives complete control over the ester's substitution (e.g., OMe, OtBu, OPh). A reaction mechanism was proposed on the basis of stoichiometric reactivity studies, spectroscopy, and DFT calculations. The new chemistry is particularly relevant for the field of Mn(I) catalysis and clearly points to a potential pathway toward irreversible catalyst deactivation.

Synthesis and structure of hypercoordinated germanate complexes with naphthalene-2,3-dialkoxide ligands

The synthesis of six-coordinated germanate complexes with naphthalene-2,3-dialkoxide ligands with alkali metals (Li, Na, and K) as counter ions are described. The molecular structures of lithium and potassium germanate complexes were clarified by X-ray diffraction analysis. Each germanium center atom is coordinated by six oxygen atoms to form slightly distorted octahedral configuration. All the compounds were thermally stable up to 300 °C determined by thermogravimetric analysis under air-flow conditions.

Preparation method of intermediate for synthesizing 3 -oxo -1 -cyclobutane carboxylic acid

The invention discloses a preparation method for synthesizing 3 -oxo -1 -cyclobutane carboxylic acid intermediate 1, 1 - bis (prop -2 -) 3, 3 -dimethoxycyclobutane -1 and 1 - dicarboxylic acid ester (compound I): using potassium isopropoxide as a base, 1 1 -1 as a solvent, and plays an important role in the yield and purity method of 3 the 3 - final product, DMAc which is prepared 1 - or -2 - I

A structural and spectroscopic investigation of octahedral platinum bis(dithiolene)phosphine complexes: Platinum dithiolene internal redox chemistry induced by phosphine association

The complexes [Pt(mdt)2] (4; mdt = methyldithiolene, [Me 2C2S2]n-), [Pt(adt)2] (5; adt = p-anisyldithiolene, [(MeO-p-C6H4)2C 2S2]n-), and [Pd(adt)2] (10) have been prepared in yields of >90% via transmetalation reactions with the corresponding [R2Sn(S2C2R′2)] complexes (R = nBu, R′ = Me; R = Me, R′ = -C 6H4-p-OMe, 3). Intraligand C-S and C-Cchelate bond lengths (～1.71 and ～1.40 A, respectively) obtained by X-ray crystallography show these compounds to be comprised of radical monoanions mdt?- and adt?-. The six-coordinate octahedral adducts [Pt(adt)2(dppe)] [6; dppe = 1,2-bis(diphenylphosphino)ethane] , trans-[Pt(adt)2(PMe3)2] (8), and trans-[Pt(mdt)2(PMe3)2] (9) have also been prepared, and crystal structures reveal dithiolene ligands that are fully reduced ene-1,2-dithiolates (C-S and C-Cchelate = ～1.77 and 1.35 A, respectively). Reduction of the dithiolene ligand thus occurs to accommodate the +IV oxidation state typical of octahedral six-coordinate platinum. The cyclic voltammogram of 5 shows two fully reversible reductions at -0.11 and -0.84 V in CH2Cl2 (vs Ag/AgCl), attributed to successive (adt?- + e- → adt2-) processes, and a reversible oxidation at +1.01 V. The cyclic voltammogram of 9 shows two reversible oxidations at +0.38 and +0.86 V, which are assigned as successive (adt2- → adt?- + e-) oxidations. Consistent with their formulation as having fully reduced dithiolene ligands, the UV-vis spectra for 6, 8, and 9 show no low-energy absorptions below 700 nm, and the S K-edge XAS spectra of 6 and 8 show dithiolene sulfur that is reduced relative to that in 5. The introduction of PMe3 to 10 did not produce the palladium analogue of 8 but rather [Pd(adt)(PMe 3)2] (11). The reaction of [PdCl2(PPh 3)2] with Li2(mdt) produced a mixture of [Pd(mdt)(PPh3)2] (12, 20%) and [(Ph3P)Pd(μ- 1,2-mdt-S,S′:S)2Pd(PPh3)] (13, 28%), with the latter having C2 symmetry with a Pd2S2 core structure folded along the S···S axis.

Compounds capable of activating cholinergic receptors

The present invention generally relates to nicotinic compounds, in the form of aryl substituted olefinic compounds, as well as pro-drug, N-oxide, metabolite and pharmaceutically acceptable salt forms thereof. Methods of modulating neurotransmitter release via administration of the compounds, pro-drugs, N-oxides and/or pharmaceutically acceptable salts are also disclosed.

STABLE BEADLETS OF LIPOPHILIC NUTRIENTS

The invention disclosed in this application relates to novel stable beadlets of lipophilic nutrients comprising an inert core having a coating comprising stabilizing antioxidant and lipophilic nutrient. The beadlets may be coated with one or more coatings to protect the lipophilic ingredients from the atmosphere, specifically the coatings can be used to protect against moisture and/or oxygen. The invention also relates to a process for the preparation of the stable beadlets. The beadlets can be used in medicines and dietary supplements intended to facilitate the reduced risk of macular degeneration, cataract, and several forms of cancer.

Compounds capable of activating cholinergic receptors

The present invention generally relates to nicotinic compounds, in the form of aryl substituted olefinic compounds, as well as pro-drug, N-oxide, metabolite and pharmaceutically acceptable salt forms thereof. Methods of modulating neurotransmitter release via administration of the compounds, pro-drugs, N-oxides and/or pharmaceutically acceptable salts are also disclosed.

Pharmaceutical compositions and methods for use

Pharmaceutical compositions incorporate aryl substituted olefinic amine compounds. Representative compounds are (3E)-N-methyl-4-[3-(5-nitro-6-aminopyridin)yl]-3-buten-1-amine, (3E)-N-methyl-4-[3-(5-(N-benzylcarboxamido)pyridin)yl]-3-buten-1-amine, (4E)-N-methyl-5-[5-(2-aminopyrimidin)yl]-4-penten-2-amine, (4E)-N-methyl-5-(3-(5-aminopyridin)yl)-4-penten-2-amine, (3E)-N-methyl-4-(3-(5-isobutoxypyridin)yl)-3-buten-1-amine, (3E)-N-methyl-4-(3-(1-oxopyridin)yl)-3-buten-1-amine, (3E)-N-methyl-4-(3-(5-ethylthiopyridin)yl)-3-buten-1-amine, (4E)-N-methyl-5-(3-(5-trifluoromethylpyridin)yl)-4-penten-2-amine and (4E)-N-methyl-5-(3-(5-hydroxypyridin)yl)-4-penten-2-amine.

PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE

Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof aryloxyalkylamines, including pyridyloxylalkylamines and phenoxyalkylamines. Exemplary compounds include dimethyl(2-(3-pyridyloxy)ethylamine, dimethyl(4-(3-pyridyloxy)butyl)amine, 2-(3-pyridyloxy)ethylamine, 4-(3-pyridyloxy)butylamine, methyl(3-(5-methoxy-3-pyridyloxy)propyl)amine, ethyl(3-(3-pyridyloxy)propyl)amine, methyl(2-(3-pyridyloxy)ethyl)amine, methyl(3-(6-methyl(3-pyridyloxy))propyl)amine, (3-(3-methoxyphenoxy)propyl)methylamine, (3-(5-chloro(3-pyridyloxy))-1-methylpropyl)methylamine, dimethyl(3-(3-pyridyloxy)propyl)amine, 3-(3-pyridyloxy)propylamine, methyl(4-(3-pyridyloxy)butyl)amine, 3-(5-chloro-3-pyridyloxy)propyl amine, methyl(3-(5-isopropoxy-3-pyridyloxy)propyl)amine, (3-(5-chloro(3-pyridyloxy))propyl) methylamine, methyl(3-(5-(phenylmethoxy)(3-pyridyloxy))propyl)amine, methyl(3-(2-methyl(3-pyridyloxy))propyl)amine, (methylethyl)(3-(3-pyridyloxy)propyl)amine, benzyl(3-(3-pyridyloxy)propyl)amine, cyclopropyl(3-(3-pyridyloxy)-propyl)amine, methyl(1-methyl-3-(3-pyridyloxy)propyl)amine, methyl(3-(3-nitrophenoxy)propyl)amine, 1-(3-chloropropoxy)-3-nitrobenzene, (3-(3-aminophenoxy)propyl)methylamine,dimethyl (3-(3-(methylamino)-propoxy)phenyl)amine, methyl(3-tricyclo[7.3.1.0]tridec-2-yloxypropyl)amine, (3-benzo[3,4-d]1,3-dioxolan-5-yloxypropyl)methylamine, 3-(4-piperidinyloxy)pyridine and 3-((3S)-3-pyrrolidinyloxy)pyridine.

PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE

Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof aryloxyalkylamines and arylthioalkylamines, including pyridyloxylalkylamines, phenoxyalkylamines, pyridylthiolalkylamines and phenylthioalkylamines. Exemplary compounds include (2-(5-bromo(3-pyridylthio))ethyl)methylamine, (2-(5-bromo(3-pyridylthio))isopropyl)methylamine, (2-(5-bromo(3-pyridylthio))propyl)methylamine, (3-(5-bromo(3-pyridylthio))propyl)methylamine, 3-((3S)-3-pyrrolidinyloxy)pyridine, 3-(4-piperidinyloxy)pyridine, 3-(1-methyl-4-piperidinyloxy)pyridine, (3-benzo[3,4-d]1,3-dioxolan-5-yloxypropyl)methylamine, and methyl(3-tricyclo[7.3.1.0]tridec-2-yloxypropyl)amine.